Rotasiil vs placebo
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- RR 0.98 [0.92, 1.04]3 studies · 11646 participantsHigh
Findings
What do systematic reviews say?
83 questions · 88 findings · 37 reviews
No studies found 20 · 22.7%GRADE not reported 6 · 6.8%Very low 22 · 25%Low 18 · 20.5%Moderate 13 · 14.8%High 9 · 10.2%
Rotavac vs placebo
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.93 [0.85, 1.02]3 studies · 8210 participantsModerate
Fluoxetine vs placebo
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
- Second‐generation antidepressants for treatment of seasonal affective disorder 2021 · Cochrane Headline outcomes onlyRR 1.07 [0.95, 1.21]1 study · 68 participantsVery low
Intravenous vs oral cyclophosphamide
Adverse events: all infections · SSNS in children
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
- Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes onlyRR 0.14 [0.03, 0.72]2 studies · 83 participantsLow
Intensive counseling vs usual family planning care
Rate of discontinuation due to all other adverse events · Women of reproductive age seeking to avoid pregnancy
Intensive counseling showed no clear difference in rate of discontinuation due to all other adverse events compared with usual family planning care (low certainty).
1 finding from 1 review
- Strategies to improve adherence and continuation of shorter‐term hormonal methods of contraception 2019 · Cochrane Headline outcomes onlyOR 0.73 [0.36, 1.47]1 study · 350 participantsLow
Efficacy and safety of a first dose of whole‐cell pertussis vaccine vs a first dose of acellular pertussis vaccine
All‐cause serious adverse events · the promotion of growth and prevention of infections in infants less than six months of age
Efficacy and safety of a first dose of whole‐cell pertussis vaccine showed no clear difference in all‐cause serious adverse events compared with a first dose of acellular pertussis vaccine (moderate certainty).
1 finding from 1 review
- Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children 2021 · Cochrane Headline outcomes onlyRR 0.94 [0.78, 1.15]15 studies · 38072 participantsModerate
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy
Adverse events ‐ All adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ All adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
- Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes onlyRR 1.14 [0.76, 1.7]2 studies · 78 participantsLow
Bamlanivimab vs placebo
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in adverse events: all grade by week 8 compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 1.12 [0.86, 1.46]1 study · 966 participantsLow
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review
- Antibiotics for preventing lower respiratory tract infections in high‐risk children aged 12 years and under 2015 · Cochrane Headline outcomes onlyRR 1.1 [0.75, 1.64]3 studies · 1344 participantsModerate
Casirivimab/imdevimab vs placebo
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in adverse events: all grades within 6 months compared with placebo (low certainty).
2 findings from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 1.14 [0.98, 1.31]1 study · 969 participantsLow
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 0.7 [0.61, 0.8]1 study · 2617 participantsHigh
Tixagevimab/cilgavimab vs placebo
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in adverse events: all grade within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 1 [0.94, 1.07]1 study · 5197 participantsLow
Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
- Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Two doses of HPV vaccine vs three doses of HPV vaccine
Overall local/injection site adverse events · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
- Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Assistive technology for vision improvement interventions vs usual care or attention control
Adverse events Falls while switching glasses · Older people living in the community
Assistive technology for vision improvement interventions showed no clear difference in adverse events Falls while switching glasses compared with usual care or attention control (low certainty).
1 finding from 1 review
- Environmental interventions for preventing falls in older people living in the community 2023 · Cochrane Headline outcomes onlyRR 1 [0.98, 1.02]1 study · 597 participantsLow
Three doses HPV vaccine vs control
Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
1 finding from 1 review
- Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes onlyRR 1.12 [1.06, 1.18]1 study · 3895 participantsHigh
Nonavalent HPV vaccine vs quadrivalent HPV vaccine
Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
- Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes onlyRR 1.07 [1.05, 1.08]3 studies · 15863 participantsHigh
Summary of findings for cholinesterase inhibitors vs placebo
Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
- Rate ratio 1.6 [1.28, 2.01]2 studies · 175 participantsLow
Hepatitis B immunoglobulin (HBIG) vs no intervention
All‐cause mortality or other serous adverse events of the newborn
1 finding from 1 review
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus 2017 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 1 participantsGRADE not reported
Hepatitis B immunoglobulin (HBIG) vs no intervention
All‐cause mortality or other serous adverse events of the mothers
1 finding from 1 review
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus 2017 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 1 participantsGRADE not reported
Chlorhexidine vs povidone‐iodine
Adverse events (maternal) ‐ skin irritation or allergic skin reaction · women undergoing caesarean section
It is very uncertain whether chlorhexidine gluconate changes adverse events (maternal) ‐ skin irritation or allergic skin reaction compared with povidone iodine (very low certainty).
1 finding from 1 review
- Skin preparation for preventing infection following caesarean section 2020 · Cochrane Headline outcomes onlyRR 0.64 [0.28, 1.46]3 studies · 1926 participantsVery low